Glow LifeTech (TSE:GLOW)
:GLOW
Top Page
Glow LifeTech
(GLOW)
Select Model
Select Model
Rating:41Neutral
Price Target:
C$0.05
▼(-11.67% Downside)
Action:DowngradedDate:01/27/26
The score is primarily held back by weak financial performance: heavy operating losses and negative free cash flow despite improving revenue and gross margin. Technicals also weigh on the score with price below major moving averages and negative MACD, while valuation is difficult to assess given negative earnings and no dividend data.
Positive Factors
Revenue growth and rising gross margin
Sustained TTM revenue growth (+27.9%) combined with a materially improved gross margin (~51.7%) signals stronger product commercialization and unit economics. Over 2–6 months this supports scaling potential and lowers the revenue threshold needed to reach operating break-even if cost discipline continues.
Negative Factors
Large operating and net losses
Very wide operating and net losses indicate the business model is not yet profitable and fixed costs substantially exceed current revenues. Persisting losses over several quarters will deplete resources and require either rapid revenue scale-up or restructuring to become sustainable.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth and rising gross margin
Sustained TTM revenue growth (+27.9%) combined with a materially improved gross margin (~51.7%) signals stronger product commercialization and unit economics. Over 2–6 months this supports scaling potential and lowers the revenue threshold needed to reach operating break-even if cost discipline continues.
Read all positive factors
Glow LifeTech (GLOW) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$9.96M
Dividend YieldN/A
Average Volume (3M)266.05K
Price to Earnings (P/E)―
Beta (1Y)0.24
Revenue Growth239.98%
EPS Growth39.01%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding181,160,580
10 Day Avg. Volume165,602
30 Day Avg. Volume266,047
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)2.41
Price to Sales (P/S)7.42
P/FCF Ratio-4.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Glow LifeTech Business Overview & Revenue Model
Company Description
Glow Lifetech Corp., a biotechnology company, focuses on producing nutraceutical and cannabinoid-based products in North America. The company engages in the commercialization of two technologies, such as MyCell Enhanced technology, a nutraceutical...
How the Company Makes Money
Glow LifeTech generates revenue through multiple streams, primarily from the sale of its health supplements and skincare products through both online and offline retail channels. The company operates a direct-to-consumer e-commerce platform, which...
Glow LifeTech Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
56
Neutral
Cash Flow
34
Negative
| Breakdown | TTM | Mar 2025 | Jun 2024 | Mar 2023 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.85M | 836.19K | 43.93K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 957.52K | 591.00K | -759.18K | -263.26K | -43.39K | 0.00 |
| EBITDA | -973.91K | -1.24M | -1.31M | -1.92M | -4.59M | -153.00K |
| Net Income | -2.28M | -2.66M | -1.59M | -2.24M | -11.31M | -153.00K |
Balance Sheet | ||||||
| Total Assets | 3.70M | 3.72M | 1.91M | 2.31M | 3.76M | 2.60K |
| Cash, Cash Equivalents and Short-Term Investments | 1.12M | 1.29M | 34.00 | 75.19K | 746.02K | 1.80K |
| Total Debt | 435.15K | 404.08K | 171.75K | 147.36K | 39.93K | 6.40K |
| Total Liabilities | 1.48M | 1.15M | 2.35M | 1.14M | 328.03K | 315.57K |
| Stockholders Equity | 2.22M | 2.57M | -433.12K | 1.16M | 3.44M | -312.97K |
Cash Flow | ||||||
| Free Cash Flow | -422.96K | -1.36M | -490.86K | -1.36M | -3.62M | -18.65K |
| Operating Cash Flow | -372.69K | -1.35M | -417.26K | -1.30M | -3.18M | -18.65K |
| Investing Cash Flow | -51.98K | 16.70K | -60.91K | 18.31K | -541.41K | -1.36K |
| Financing Cash Flow | 657.99K | 2.62M | 445.01K | 491.44K | 4.59M | 2.93K |
Glow LifeTech Technical Analysis
Positive
0.06
Price Trends
0.05
Positive
0.06
Positive
0.05
Positive
Market Momentum
<0.01
Negative
60.94
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:GLOW, the sentiment is Positive. The current price of 0.06 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.05, and above the 200-day MA of 0.05, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 60.94 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:GLOW.
Glow LifeTech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | C$11.98M | -6.26 | -78.88% | ― | -72.51% | -170.13% | |
42 Neutral | C$11.74M | -5.25 | 21.59% | ― | ― | -120.00% | |
41 Neutral | C$9.96M | -20.15 | -95.68% | ― | 239.98% | 39.01% | |
41 Neutral | C$5.46M | -3.10 | ― | ― | ― | ― |
* Healthcare Sector Average
TSE:GLOW
Glow LifeTech
0.06
>-0.01
-8.33%
TSE:CSCI
COSCIENS Biopharma
2.28
-1.26
-35.50%
TSE:KNE
Kane Biotech
0.03
-0.07
-70.00%
TSE:QPT
Quest Pharmatech
0.03
-0.03
-50.00%
TSE:PREV
PreveCeutical Medical
0.02
0.00
0.00%
TSE:MDMA
PharmAla Biotech Holdings, Inc.
0.11
-0.04
-26.67%
Glow LifeTech Corporate Events
Business Operations and StrategyProduct-Related Announcements
Glow Lifetech Pushes National Cannabis Expansion with Manitoba Entry and New Brunswick Portfolio Boost
Positive
Feb 3, 2026
Glow Lifetech Corp. is extending its MOD and .decimal cannabis brands into Manitoba and broadening its product portfolio in New Brunswick as part of its ongoing national expansion across Canada. The company has secured eight initial product listin...
Business Operations and StrategyProduct-Related Announcements
Glow Lifetech Enters Canadian Medical Cannabis Market with National Mendo Launch
Positive
Jan 7, 2026
Glow Lifetech has entered the Canadian medical cannabis market by launching its MOD and .decimal product portfolio on the national Mendo Medical Cannabis platform, making 14 SKUs of its next-generation cannabis products available to registered med...
Business Operations and StrategyFinancial Disclosures
Glow Lifetech Achieves Record Q3 2025 Results and Positive Cash Flow
Positive
Nov 25, 2025
Glow Lifetech Corp. reported a record-breaking Q3 2025 with a 193% year-over-year revenue growth and achieved its first positive cash flow from operations. This milestone reflects the company’s strong commercial momentum, disciplined cost ma...
Business Operations and StrategyFinancial Disclosures
Glow Lifetech Achieves Debt-Free Status, Strengthens Financial Position
Positive
Nov 19, 2025
Glow Lifetech Corp has achieved a debt-free status, marking a significant milestone in its financial management strategy. By eliminating over $1.4 million in debt, the company has strengthened its balance sheet, reduced interest expenses, and enha...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.